{"id":2936,"date":"2025-09-15T11:22:03","date_gmt":"2025-09-15T11:22:03","guid":{"rendered":"https:\/\/wallstreetendeavor.com\/?p=2936"},"modified":"2025-09-23T10:43:20","modified_gmt":"2025-09-23T10:43:20","slug":"buy-sell-or-hold-hims-hers-stock-surges-64","status":"publish","type":"post","link":"https:\/\/wallstreetendeavor.com\/de\/pharmaceutical\/buy-sell-or-hold-hims-hers-stock-surges-64\/","title":{"rendered":"Buy, Sell, or Hold: Hims & Hers Stock Surges 64%"},"content":{"rendered":"

The recent surge in shares of Hims & Hers Health (NYSE: HIMS)<\/a><\/strong> has outpaced both peers and broader market benchmarks. For comparison, Teladoc Health is down nearly 9%, Amwell has slid more than 14%, and the S&P 500 has gained just under 21%.<\/p>\n\n\n\n

That kind of outperformance raises an obvious question: is the momentum sustainable?<\/p>\n\n\n\n

What Is Hims & Hers?<\/h3>\n\n\n\n

Hims & Hers Health is a digital health and wellness platform built on a straightforward idea: cut out the middleman.<\/p>\n\n\n\n

By connecting patients directly with licensed providers online and shipping treatments straight to their doors, the company removes much of the hassle and cost of traditional healthcare systems.<\/p>\n\n\n\n

This direct-to-consumer approach has proven highly effective, especially among younger customers who tend to prefer more private, telehealth services.<\/p>\n\n\n\n

Growth Is Hitting Its Stride<\/h3>\n\n\n\n

Second-quarter results gave bulls plenty to cheer about. Revenues and earnings exceeded expectations, driven by a sharp increase in subscribers and higher monthly revenue per user.<\/p>\n\n\n\n

The company also delivered operating margin expansion, a sign that its digital-first model is scaling efficiently.<\/p>\n\n\n\n

Hims & Hers is guiding for full-year 2025 revenue of $2.3\u2013$2.4 billion, a massive 56\u201363% jump from 2024. That outlook suggests management is confident in the durability of subscriber growth, engagement, and conversion.<\/p>\n\n\n\n

Expanding Beyond the U.S.<\/h3>\n\n\n\n

A big part of the HIMS story is international growth. The company\u2019s acquisition of ZAVA, a European digital health platform, accelerates its entry into the U.K., Germany, France, and Ireland.<\/p>\n\n\n\n

With 1.3 million active ZAVA customers and millions of completed consultations, Hims & Hers is positioning itself to capture share in large, underserved markets while leveraging its existing digital infrastructure.<\/p>\n\n\n\n

Betting on AI and Personalized Care<\/h3>\n\n\n\n

Hims & Hers is also putting serious capital behind technology. Its $870 million convertible note offering will fuel acquisitions, global rollouts, and AI-driven personalization. The recent hiring of Mo Elshenawy as CTO\u2014an executive with deep expertise in AI and large-scale systems\u2014signals that management sees digital innovation as central to its competitive edge.<\/p>\n\n\n\n

This focus could allow HIMS to deliver standardized, yet personalized care at scale\u2014an approach investors should be watching closely.<\/p>\n\n\n\n

<\/p>","protected":false},"excerpt":{"rendered":"

The past six months have been a windfall for Hims & Hers Health\u2019s shareholders as the stock surged 64%. Is now the right time to buy HIMS? Or is this rally more about investor enthusiasm than fundamentals?<\/p>","protected":false},"author":2,"featured_media":2937,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[48,32,55,8,58,57,7,63],"tags":[64,68,72,33,70,31],"class_list":["post-2936","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotech","category-pharma-general","category-pharma-industry","category-investing","category-latest-us-stock-market-news","category-pharma-investments","category-pharmaceutical","category-worthy-endeavors","tag-biotech","tag-finance","tag-industry","tag-investing","tag-north-america","tag-pharmaceutical"],"acf":{"featured_video_oembed":"","featured_post_summary":"","post_source":""},"_links":{"self":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/2936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/comments?post=2936"}],"version-history":[{"count":2,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/2936\/revisions"}],"predecessor-version":[{"id":2940,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/2936\/revisions\/2940"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/media\/2937"}],"wp:attachment":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/media?parent=2936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/categories?post=2936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/tags?post=2936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}